A421infliximab, ustekinumab) was explored. From the annual eligible psoriasis population (N= 16,322), 5% (n= 816), 11% (n= 1,795), and 18% (n= 2,938) were assumed to be treated with apremilast for the first, second, and third years. A local expert panel provided detailed resource consumption information. Total cost included drug acquisition based on drug doses from summaries of product characteristics (ex-factory price with mandatory deduction), administration (parenteral drugs), and monitoring costs. Unitary costs (€ , 2014) were obtained from national databases. Results: Total budget for the scenario without apremilast was € 193,677,634, € 192,945,426, and € 192,077,291 in the first, second, and third years. Pharmaceutical cost represented 95% of the total. Following apremilast introduction, total budgets were reduced by € 2,194,450, € 4,827,791, and € 7,900,021 in the first, second, and third years. Incremental drug costs/patient comparing the scenario with apremilast vs. without apremilast were € −134.44 (−1.13%), € −295.78 (−2.50%), and € −484.00 (−4.11%) in the first, second, and third years. ConClusions: Apremilast treatment for psoriasis patients who have failed to respond to, have a contraindication to, or are intolerant of other systemic therapy would imply a budget impact decrease on overall healthcare expenditure for NHS. This analysis was limited in that the model did not consider cost-effectiveness issues.